Results 71 to 80 of about 5,801 (166)

Molnupiravir for the treatment of COVID-19 outpatients: An updated meta-analysis

Journal of Microbiology, Immunology and Infection
Background: The majority of available data on molnupiravir come from an unvaccinated COVID-19 population. Therefore, we conducted this meta-analysis to integrate evidence from recent randomized controlled trials (RCTs) as well as observational studies ...
Huzaifa Ahmad Cheema, Saleha Abdul Rab, Momina Butt, Uzair Jafar, Abia Shahid, Aqeeb Ur Rehman, Ka Yiu Lee, Syeda Sahra, Ranjit Sah   +8 more
doaj   +1 more source

Abstracts From AIDS 2026, the 26th International AIDS Conference, 26 – 31 July 2026 Rio de Janeiro, Brazil & virtual

Journal of the International AIDS Society, Volume 29, Issue S4, July 2026.
wiley   +1 more source

Prevention is better than healing. Clinical and economic implications of oral antiviral agents in COVID-19: a prospective study

Italian Journal of Medicine
COVID-19 represents a threat for frailty patients. This study compares molnupiravir and nirmatrelvir for fragile COVID- 19 patients' efficacy, safety, and cost.
Filomena Pietrantonio, Francesco Rosiello, Matteo Ruggeri, Maria Sofia Cattaruzza, Antonio Vinci, Margherita Lordi, Enrica Cipriano   +6 more
doaj   +1 more source

Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir Compared with Molnupiravir in Patients at High Risk for Progression to Severe COVID-19 in Japan

Journal of Health Economics and Outcomes Research
# Background Nirmatrelvir/ritonavir (NMV/r) and molnupiravir are oral antiviral drugs approved for the treatment of early symptomatic patients with mild to moderate COVID-19 at high risk of progression to severe disease in Japan.
Akira Yuasa, Hiroyuki Matsuda, Yosuke Fujii, Tendai Mugwagwa, Yuki Kado, Mizuki Yoshida, Koichi Murata, Yoshiaki Gu   +7 more
doaj   +1 more source

Synthesis of Molnupiravir [PDF]

Synfacts, 2022
openaire   +1 more source

Comprehensive genotoxicity and carcinogenicity assessment of molnupiravir

Toxicological Sciences
Abstract Molnupiravir is registered or authorized in several countries as a 5-d oral coronavirus disease 2019 treatment for adults. Molnupiravir is a prodrug of the antiviral ribonucleoside β-D-N4-hydroxycytidine (NHC) that distributes into cells, where it is phosphorylated to its pharmacologically active ribonucleoside triphosphate (NHC-
Patricia A Escobar, Zhanna Sobol, Randy R Miller, Sandrine Ferry-Martin, Angela Stermer, Binod Jacob, Nagaraja Muniappa, Rosa I Sanchez, Kerry T Blanchard, Alema Galijatovic-Idrizbegovic, Rupesh P Amin, Sean P Troth   +11 more
openaire   +2 more sources

A Phase 2a, Randomized, Placebo-Controlled Human Challenge Trial to Evaluate the Efficacy and Safety of Molnupiravir in Healthy Participants Inoculated with Respiratory Syncytial Virus

Pulmonary Therapy
Introduction Human respiratory syncytial virus (RSV) infections can result in hospitalization and/or death among vulnerable populations. Molnupiravir is a prodrug of ß-D-N4-hydroxycytidine, which has broad-spectrum preclinical activity against RNA ...
Mickie H. Cheng, Alex J. Mann, Brian M. Maas, Tian Zhao, Melissa Bevan, Andrea K. Schaeffer, Laura E. Liao, Andrew P. Catchpole, David W. Hilbert, S. Aubrey Stoch, Carisa S. De Anda   +10 more
doaj   +1 more source

Effect of Nucleic Acid Analog Administration on Fluctuations in the Albumin-to-Globulin Ratio in Cats with Feline Infectious Peritonitis

Animals
Background: feline infectious peritonitis (FIP) is a fatal disease in cats classified as either effusive (‘wet’), non-effusive (‘dry’), or a mixture of both forms (‘mixed’).
Masato Katayama, Yukina Uemura, Daichi Katori   +2 more
doaj   +1 more source

Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study

Scientific Reports
This study aimed to explore the effectiveness and safety of azvudine, nirmatrelvir/ritonavir, and molnupiravir in adult patients with mild-to-moderate COVID-19.
Mei-Ping Chen, Di-Xuan Jiang, Jia-Xi Rang, Hai-Bo Zhuo, Zhi-Guo Zhou   +4 more
doaj   +1 more source

Clinical Outcomes of Early Antiviral Treatment for COVID-19 in a Japanese Long-Term Care Facility With Limited Resources: A Retrospective Study of 107 Residents. [PDF]

Cureus
Kudeken N.
europepmc   +1 more source